文献速递其他结缔组织病

尼达尼布抑制Fra2系统性硬化症小鼠模型的巨噬细胞活化并改善血管与纤维化表现

Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.
PubMed 文献 · Ann Rheum Dis · 2017-08-16

本研究在fos相关抗原2(Fra2)系统性硬化症(SSc)小鼠模型中评估尼达尼布的作用,发现其可抑制肺血管平滑肌细胞增殖、减少微血管内皮细胞凋亡、减轻肺、皮肤和心肌纤维化,并与单核细胞M2极化和M2巨噬细胞减少相关。结论提示尼达尼布靶向SSc核心特征,可能对SSc相关间质性肺病的III期临床试验有直接意义。

要点

  • 尼达尼布抑制肺血管平滑肌细胞增殖,防止肺小动脉管壁增厚和管腔闭塞。
  • 尼达尼布抑制微血管内皮细胞凋亡并减轻毛细血管稀疏,伴血清VEGF水平正常化。
  • 尼达尼布阻断肌成纤维细胞分化,减少肺、皮肤和心肌纤维化,伴M2巨噬细胞减少。

核心结论

  • 尼达尼布靶向Fra2转基因小鼠SSc的核心特征,改善肺动脉高压、破坏性微血管病及肺和皮肤纤维化的组织学表现。
  • 这些数据可能对正在进行的尼达尼布治疗SSc相关间质性肺病的III期临床试验具有直接意义。

研究设计与样本

  • 本研究为动物实验研究,使用fos相关抗原2(Fra2)系统性硬化症(SSc)小鼠模型分析尼达尼布的作用。
  • 研究分析尼达尼布对肺血管平滑肌细胞(PVSMC)增殖与管腔闭塞、微血管内皮细胞(MVEC)凋亡、成纤维细胞活化与肌成纤维细胞分化及细胞外基质积累的影响。
  • 研究还分析尼达尼布对SSc发病关键介质水平及巨噬细胞极化的影响。

主要发现

  • 尼达尼布抑制PVSMC增殖,防止血管壁增厚和肺动脉管腔闭塞。
  • 尼达尼布抑制MVEC凋亡并减轻Fra2转基因小鼠的毛细血管稀疏,这些效应与尼达尼布治疗Fra2小鼠血清血管内皮生长因子水平正常化相关。
  • 尼达尼布有效阻断肌成纤维细胞分化,减少Fra2转基因小鼠的肺、皮肤和心肌纤维化。
  • 尼达尼布的抗纤维化效应与单核细胞M2极化受损及M2巨噬细胞数量减少相关。

临床怎么用

  • 在Fra2小鼠模型中,尼达尼布同时改善肺血管病变、微血管病变和纤维化,支持其在SSc相关间质性肺病中的进一步临床评估。
  • 尼达尼布的抗纤维化作用与抑制单核细胞M2极化和减少M2巨噬细胞相关,提示巨噬细胞极化可能是其作用环节之一。

局限性

  • 本研究为Fra2小鼠模型的动物实验,原文未报告人体研究数据或临床终点。
  • 原文未报告样本量、剂量、P值等具体数值,相关细节无法从摘要中获取。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nintedanib is an inhibitor targeting platelet-derived growth factor receptor, fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases that has recently been approved for the treatment of idiopathic pulmonary fibrosis. The aim of this study was to analyse the effects of nintedanib in the fos-related antigen-2 (Fra2) mouse model of systemic sclerosis (SSc). METHODS: The effects of nintedanib on pulmonary arterial hypertension with proliferation of pulmonary vascular smooth muscle cells (PVSMCs) and luminal occlusion, on microvascular disease with apoptosis of microvascular endothelial cells (MVECs) and on fibroblast activation with myofibroblast differentiation and accumulation of extracellular matrix were analysed. We also studied the effects of nintedanib on the levels of key mediators involved in the pathogenesis of SSc and on macrophage polarisation. RESULTS: Nintedanib inhibited proliferation of PVSMCs and prevented thickening of the vessel walls and luminal occlusion of pulmonary arteries. Treatment with nintedanib also inhibited apoptosis of MVECs and blunted the capillary rarefaction in Fra2-transgenic mice. These effects were associated with a normalisation of the serum levels of vascular endothelial growth factor in Fra2 mice on treatment with nintedanib. Nintedanib also effectively blocked myofibroblast differentiation and reduced pulmonary, dermal and myocardial fibrosis in Fra2-transgenic mice. The antifibrotic effects of nintedanib were associated with impaired M2 polarisation of monocytes and reduced numbers of M2 macrophages. CONCLUSION: Nintedanib targets core features of SSc in Fra2-transgenic mice and ameliorates histological features of pulmonary arterial hypertension, destructive microangiopathy and pulmonary and dermal fibrosis. These data might have direct implications for the ongoing phase III clinical trial with nintedanib in SSc-associated interstitial lung disease.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Huang J, Maier C, Zhang Y, et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis. 2017. PMID: 28814429. doi:10.1136/annrheumdis-2016-210823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。